Exploitation of drug-induced Bcl-2 overexpression for restoring normal apoptosis function: A promising new approach to the treatment of multidrug resistant cancer

Cancer Letters

Volumn 253, Issue 1, 2007, Pages 115-123

  Su, Yaming ^a   Zhang, Xiaoping ^a   Sinko, Patrick J ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Acute lymphoblastic leukemia; Bcl 2; Bcl 2 inhibitor; Camptothecins; Multidrug resistance

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; CAMPTOTHECIN; DNA FRAGMENT; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LEUKEMIA; MEMBRANE POTENTIAL; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT INDICATION;

APOPTOSIS; BENZOPYRANS; CASPASES; DNA FRAGMENTATION; DRUG RESISTANCE, MULTIPLE; ENZYME ACTIVATION; GENES, BCL-2; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MEMBRANE POTENTIALS; NITRILES; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 34249904410     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.01.018     Document Type: Article

References (34)

1. Reed J.C. Bcl-2 family proteins. Oncogene 17 (1998) 3225-3236
2. Zhang Y., Fujita N., and Tsuruo T. p21Wafl/Cipl acts in synergy with bcl-2 to confer multidrug resistance in a camptothecin-selected human lung-cancer cell line. Int. J. Cancer 83 (1999) 790-797
3. Chekhun V.F., Lukyanova N.Y., Urchenko O.V., and Kulik G.I. The role of expression of the components of proteome in the formation of molecular profile of human ovarian carcinoma A2780 cells sensitive and resistant to cisplatin. Exp. Oncol. 27 (2005) 191-195
4. Tu Y., Xu F.H., Liu J., Vescio R., Berenson J., Fady C., et al. Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood 88 (1996) 1805-1812
5. Kitada S., Pedersen I.M., Schimmer A.D., and Reed J.C. Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene 21 (2002) 3459-3474
6. Mounier N., Briere J., Gisselbrecht C., Emile J.F., Lederlin P., Sebban C., et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101 (2003) 4279-4284
7. Kaufmann S.H., and Vaux D.L. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 22 (2003) 7414-7430
8. Juin P., Geneste O., Raimbaud E., and Hickman J.A. Shooting at survivors: Bcl-2 family members as drug targets for cancer. Biochim. Biophys. Acta 1644 (2004) 251-260
9. Jansen B., Schlagbauer-Wadl H., Brown B.D., Bryan R.N., van Elsas A., Muller M., et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med. 4 (1998) 32-234
10. Wacheck V., Losert D., Gunsberg P., Vornlocher H.P., Hadwiger P., Geick A., et al. Small interfering RNA targeting bcl-2 sensitizes malignant melanoma. Oligonucleotides 13 (2003) 393-400
11. Webb A., Cunningham D., Cotter F., Clarke P.A., di Stefano F., Ross P., et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349 (1997) 1137-1141
12. Gautschi O., Tschopp S., Olie R.A., Leech S.H., Simoes-Wust A.P., Ziegler A., et al. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J. Natl. Cancer Inst. 93 (2001) 463-471
13. Petros A.M., Medek A., Nettesheim D.G., Kim D.H., Yoon H.S., Swift K., et al. Solution structure of the antiapoptotic protein bcl-2. Proc. Natl. Acad. Sci. USA 98 (2001) 3012-3017
14. Muchmore S.W., Sattler M., Liang H., Meadows R.P., Harlan J.E., Yoon H.S., et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381 (1996) 35-341
15. Wang J.L., Zhang Z.J., Choksi S., Shan S., Lu Z., Croce C.M., et al. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 60 (2000) 1498-1502
16. Wang J.L., Liu D., Zhang Z.J., Shan S., Han X., Srinivasula S.M., et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. USA 97 (2000) 7124-7129
17. Hermine O., Haioun C., Lepage E., d'Agay M.F., Briere J., Lavignac C., et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 87 (1996) 265-272
18. Hill M.E., MacLennan K.A., Cunningham D.C., Vaughan Hudson B., Burke M., Clarke P., et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood 88 (1996) 1046-1051
19. Tamura H., Kohchi C., Yamada R., Ikeda T., Koiwai O., Patterson E., et al. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res. 19 (1991) 69-75
20. Lickliter J.D., Wood N.J., Johnson L., McHugh G., Tan J., Wood F., et al. HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death. Leukemia 17 (2003) 2074-2080
21. Skommer J., Wlodkowic D., Matto M., Eray M., and Pelkonen J. HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells. Leuk Res. (2005)
22. Marzo I., Brenner C., Zamzami N., Susin S.A., Beutner G., Brdiczka D., et al. The permeability transition pore complex: a target for apoptosis regulation by caspases and bcl-2-related proteins. J. Exp. Med. 187 (1998) 1261-1271
23. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., et al. Cytochrome c and dATP-dependent formation of Apaf-l/caspase-9 complex initiates an apoptotic protease cascade. Cell 91 (1997) 479-489
24. Reed J.C. Apoptosis-targeted therapies for cancer. Cancer Cell 3 (2003) 17-22
25. Letai A. Pharmacological manipulation of Bcl-2 family members to control cell death. J. Clin. Invest. 115 (2005) 2648-2655
26. Sonneveld P., Durie B.G., Lokhorst H.M., Marie J.P., Solbu G., Suciu S., et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet 340 (1992) 255-259
27. Linsenmeyer M.E., Jefferson S., Wolf M., Matthews J.P., G Board P., and Woodcock D.M. Levels of expression of the mdrl gene and glutathione S-transferase genes 2 and 3 and response to chemotherapy in multiple myeloma. Br. J. Cancer 65 (1992) 471-475
28. Ishikawa H., Kawano M.M., Okada K., Tanaka H., Tanabe O., Sakai A., et al. Expressions of DNA topoisomerase I and II gene and the genes possibly related to drug resistance in human myeloma cells. Br. J. Haematol. 83 (1993) 68-74
29. Hanada M., Delia D., Aiello A., Stadtmauer E., and Reed J.C. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82 (1993) 1820-1828
30. Ogretmen B., and Safa A.R. Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells. Int. J. Cancer 67 (1996) 608-614
31. Ferlini C., Raspaglio G., Mozzetti S., Distefano M., Filippetti F., Martinelli E., et al. Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol. Pharmacol. 64 (2003) 51-58
32. Leone M., Zhai D., Sareth S., Kitada S., Reed J.C., and Pellecchia M. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res. 63 (2003) 8118-8121
33. Becattini B., Kitada S., Leone M., Monosov E., Chandler S., Zhai D., et al. In-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem. Biol. 11 (2004) 389-395
34. Lin B., Kolluri S.K., Lin F., Liu W., Han Y.H., Cao X., et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 116 (2004) 527-540